Management of IgA Vasculitis in Children
Most children with IgA vasculitis (IgAV) require only supportive care with analgesia and monitoring, while corticosteroids should be reserved for severe gastrointestinal manifestations, testicular involvement, or significant nephritis 1, 2.
Initial Assessment and Risk Stratification
When a child presents with suspected IgAV, immediately assess for:
- Palpable purpura (typically lower extremities and buttocks)
- Joint involvement (arthralgia or arthritis)
- Gastrointestinal symptoms (abdominal pain, vomiting, bleeding)
- Renal involvement (hematuria, proteinuria, hypertension)
- Testicular pain or swelling
Critical pitfall: Initial urinalysis may be normal despite evolving systemic disease and even hypertension 3. Serial monitoring is essential regardless of initial laboratory findings.
Management by Disease Severity
Uncomplicated IgAV (Skin and Joint Involvement Only)
For children with isolated purpura and/or arthralgia:
- Supportive care with adequate analgesia (NSAIDs or acetaminophen) 1, 2
- No corticosteroids needed 1, 2
- Outpatient monitoring with serial urinalysis and blood pressure checks
Severe Gastrointestinal Involvement
When children develop severe abdominal pain, persistent vomiting, or gastrointestinal bleeding:
- Corticosteroids are indicated (typically prednisolone 1-2 mg/kg/day) 1, 4, 2
- Hospitalization for monitoring and exclusion of intussusception
- Imaging (ultrasound) to rule out surgical complications
Testicular Involvement
- Corticosteroids recommended for symptomatic scrotal edema or pain 1, 2
- Urgent urological assessment to exclude testicular torsion
Renal Management (IgAV Nephritis)
Monitoring Protocol
All children with IgAV require:
- Weekly urinalysis and blood pressure monitoring for at least 4-6 weeks 1, 5
- Continue monitoring for 6-12 months as nephritis can develop late 1, 5
Treatment Based on Nephritis Severity
Mild nephritis (isolated microscopic hematuria or proteinuria <1 g/day):
- ACE inhibitor or ARB therapy for persistent proteinuria 6, 2
- Close monitoring without immunosuppression 2
Moderate nephritis (proteinuria >1 g/day but <3.5 g/day with preserved renal function):
- ACE inhibitor/ARB as first-line 6, 2
- Consider corticosteroids (oral prednisolone) 7, 2
- Evidence suggests steroids show favorable overall efficacy 7
Severe nephritis (nephrotic-range proteinuria, declining renal function, or crescentic disease on biopsy):
- High-dose corticosteroids (IV methylprednisolone followed by oral prednisolone) 2
- Add second-line immunosuppression: cyclophosphamide, mycophenolate mofetil, or azathioprine 4, 2
- Consider renal biopsy to guide therapy intensity 1, 5
Rapidly progressive disease (≥50% eGFR decline over ≤3 months with crescentic glomerulonephritis):
- Cyclophosphamide plus systemic glucocorticoids following ANCA-vasculitis protocols 6
- Consider plasma exchange in life-threatening situations 4
Evidence Nuances
The 2024 UK national recommendations 1 and 2019 European SHARE guidelines 2 provide the most comprehensive pediatric-specific guidance, emphasizing that most children recover fully with supportive care alone. The 2025 IPNA recommendations 5 acknowledge the paucity of high-quality pediatric evidence and difficulty extrapolating from adult studies.
A 2025 network meta-analysis 7 found steroids most effective overall, though safety concerns require consideration. Newer therapies like rituximab show promise for refractory cases 4, but evidence in children remains limited.
Important caveat: The KDIGO 2025 guideline 6 focuses primarily on IgA nephropathy (not IgAV), though principles for managing severe nephritis overlap. SGLT2 inhibitors and sparsentan mentioned in KDIGO are not yet established in pediatric IgAV nephritis.